Compositions and methods for treatment and prevention of cardiovascular diseases

Patent metadata

Field	Value
Publication number	US-2018153993-A1
Application number	US-201715789853-A
Country	US
Kind code	A1
Filing date	Oct 20, 2017
Priority date	Dec 7, 2016
Publication date	Jun 7, 2018
Grant date	—

Abstract

The present invention provides novel methods for the prevention and treatment of cardiovascular diseases and inflammatory diseases by modulating the Hippo-YAP signaling pathway. Also provided are methods for identifying compounds that are capable of modulating the Hippo-YAP signaling pathway and are therefore useful for the prevention and treatment of cardiovascular diseases and inflammatory diseases.

First claim

1 . A method for treating or preventing a cardiovascular disease or an inflammatory disease in a subject, comprising administering to the subject a composition comprising an effective amount of an inhibitor of YAP or an activator of integrin β3.

2 . The method of claim 1 , wherein the subject has been diagnosed with a cardiovascular disease or an inflammatory disease.

3 . The method of claim 1 , wherein the subject is at risk of a cardiovascular disease or an inflammatory disease but has not been diagnosed with a cardiovascular disease or an inflammatory disease.

4 . The method of claim 2 , wherein the composition is a medicament administered by injection or oral ingestion.

5 . The method of claim 2 , wherein the composition is a dietary supplement administered by oral ingestion.

6 . A method for identifying a modulator of integrin-YAP/TAZ signaling pathway, comprising the steps of:
(a) placing an endothelial cell under unidirectional shear stress or under disturbed flow; (b) contacting the cell with a candidate compound and determining YAP phosphorylation level at Ser127; and (c) comparing the YAP phosphorylation level at Ser127 obtained in step (b) with YAP phosphorylation level at Ser127 in a control endothelial cell under unidirectional shear stress but not contacted with the candidate compound; and (d) determining the candidate compound as an inhibitor of YAP or activator of integrin β3 when the YAP phosphorylation level at Ser127 obtained in step (b) is greater than the YAP phosphorylation level at Ser127 in the control endothelial cell, and determining the candidate compound as an activator of YAP or inhibitor of integrin β3 when the YAP phosphorylation level at Ser127 obtained in step (b) is less than the YAP phosphorylation level at Ser127 in the control endothelial cell.

7 . The method of claim 6 , wherein the endothelial cell is a human umbilical vein endothelial cell (HUVEC) or human aortic endothelial cell (HAEC).

8 . (canceled)

9 . (canceled)

10 . A method for identifying a modulator of integrin-YAP/TAZ signaling pathway, comprising the steps of:
(a) placing an endothelial cell under unidirectional shear stress or under disturbed flow; (b) contacting the cell with a candidate compound and determining integrin β3-Gβ13 association level; and (c) comparing the integrin β3-Gα13 association level obtained in step (b) with integrin β3-Gα13 association level in a control endothelial cell under unidirectional shear stress but not contacted with the candidate compound; and (d) determining the candidate compound as an inhibitor of YAP or activator of integrin β3 when the integrin β3-Gα13 association level obtained in step (b) is greater than the integrin β3-Gα13 association level in the control endothelial cell, and determining the candidate compound as an activator of YAP or inhibitor of integrin β3 when the integrin β3-Gα13 association level obtained in step (b) is less than the integrin β3-Gα13 association level in the control endothelial cell.

11 . The method of claim 10 , wherein the endothelial cell is a human umbilical vein endothelial cell (HUVEC) or human aortic endothelial cell (HAEC).

12 . (canceled)

13 . (canceled)

14 . A kit for treating or preventing a cardiovascular disease or an inflammatory disease in a subject, comprising (1) a composition comprising an effective amount of an activator of YAP or inhibitor of integrin β3; and (2) another agent effective for treating or preventing a cardiovascular disease or an inflammatory disease.

15 . The kit of claim 14 , further comprising an instruction manual.

Assignees

• Univ Hong Kong Chinese

Inventors

• Huang Yu
• Wang Li

Classifications

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07K14/4705

  stimulating, promoting or activating activity · CPC title

• C07K14/4703 Primary

  Inhibitors; Suppressors · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title